JP2010174030A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010174030A5 JP2010174030A5 JP2010074109A JP2010074109A JP2010174030A5 JP 2010174030 A5 JP2010174030 A5 JP 2010174030A5 JP 2010074109 A JP2010074109 A JP 2010074109A JP 2010074109 A JP2010074109 A JP 2010074109A JP 2010174030 A5 JP2010174030 A5 JP 2010174030A5
- Authority
- JP
- Japan
- Prior art keywords
- antibacterial agent
- antibiotic
- clarithromycin
- tetracycline
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003242 anti bacterial agent Substances 0.000 claims 5
- 230000003115 biocidal effect Effects 0.000 claims 3
- 239000004098 Tetracycline Substances 0.000 claims 2
- 229960002626 clarithromycin Drugs 0.000 claims 2
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims 2
- 229960002180 tetracycline Drugs 0.000 claims 2
- 229930101283 tetracycline Natural products 0.000 claims 2
- 235000019364 tetracycline Nutrition 0.000 claims 2
- 150000003522 tetracyclines Chemical class 0.000 claims 2
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 claims 1
- 206010061041 Chlamydial infection Diseases 0.000 claims 1
- 208000035086 Chlamydophila Infections Diseases 0.000 claims 1
- 229930189077 Rifamycin Natural products 0.000 claims 1
- ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 claims 1
- 229960004099 azithromycin Drugs 0.000 claims 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229960000885 rifabutin Drugs 0.000 claims 1
- 229960003292 rifamycin Drugs 0.000 claims 1
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical group OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 claims 1
- 229960005224 roxithromycin Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPP4376 | 1998-06-30 | ||
| AUPP4376A AUPP437698A0 (en) | 1998-06-30 | 1998-06-30 | Methods for treatment of coronary, carotid and other vascular disease |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000557825A Division JP4651816B2 (ja) | 1998-06-30 | 1999-06-30 | クラミジアおよび類似細菌の感染と関連のある障害の治療のための方法および組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013076511A Division JP2013147504A (ja) | 1998-06-30 | 2013-04-02 | クラミジアおよび類似細菌の感染と関連のある障害の治療のための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010174030A JP2010174030A (ja) | 2010-08-12 |
| JP2010174030A5 true JP2010174030A5 (enExample) | 2011-06-16 |
| JP5335726B2 JP5335726B2 (ja) | 2013-11-06 |
Family
ID=3808619
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000557825A Expired - Lifetime JP4651816B2 (ja) | 1998-06-30 | 1999-06-30 | クラミジアおよび類似細菌の感染と関連のある障害の治療のための方法および組成物 |
| JP2010074109A Expired - Lifetime JP5335726B2 (ja) | 1998-06-30 | 2010-03-29 | クラミジアおよび類似細菌の感染と関連のある障害の治療のための方法および組成物 |
| JP2013076511A Pending JP2013147504A (ja) | 1998-06-30 | 2013-04-02 | クラミジアおよび類似細菌の感染と関連のある障害の治療のための方法および組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000557825A Expired - Lifetime JP4651816B2 (ja) | 1998-06-30 | 1999-06-30 | クラミジアおよび類似細菌の感染と関連のある障害の治療のための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013076511A Pending JP2013147504A (ja) | 1998-06-30 | 2013-04-02 | クラミジアおよび類似細菌の感染と関連のある障害の治療のための方法および組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6475518B1 (enExample) |
| EP (2) | EP1093363B1 (enExample) |
| JP (3) | JP4651816B2 (enExample) |
| AT (1) | ATE345115T1 (enExample) |
| AU (2) | AUPP437698A0 (enExample) |
| CA (2) | CA2684402C (enExample) |
| DE (1) | DE69934010T2 (enExample) |
| ES (2) | ES2278449T3 (enExample) |
| NZ (1) | NZ509504A (enExample) |
| WO (1) | WO2000001378A1 (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6710033B1 (en) | 1996-08-14 | 2004-03-23 | Vanderbilt University | Methods and treatment of multiple sclerosis |
| US6258532B1 (en) | 1997-08-14 | 2001-07-10 | Vanderbilt University | Methods for in vitro susceptibility testing of chlamydia |
| US6756369B2 (en) * | 1997-05-06 | 2004-06-29 | Vanderbilt University | Diagnosis and management of infection caused by Chlamydia |
| US6890526B2 (en) | 1997-05-06 | 2005-05-10 | Vanderbilt University | Methods and reagents for the treatment of multiple sclerosis |
| EP1166117A2 (en) * | 1999-03-19 | 2002-01-02 | Vanderbilt University | Diagnosis and treatment of multiple sclerosis |
| US6991807B2 (en) * | 2000-02-24 | 2006-01-31 | Advancis Pharmaceutical, Corp. | Antibiotic composition |
| AU3984101A (en) * | 2000-02-24 | 2001-09-03 | Advanced Pharma Inc | Antibiotic and antifungal compositions |
| UA77654C2 (en) * | 2000-03-22 | 2007-01-15 | Upjohn Co | Compressed tablet of linezolide |
| US6514529B2 (en) | 2000-03-22 | 2003-02-04 | Pharmacia & Upjohn Company | Oxazolidinone tablet formulation |
| IT1318459B1 (it) | 2000-04-11 | 2003-08-25 | Zambon Spa | Uso del tiamfenicolo e di suoi derivati per la preparazione dicomposizioni farmaceutiche utili per il trattamento di infezioni da |
| US20020169112A1 (en) * | 2001-05-08 | 2002-11-14 | Luc Montagnier | Combined treatments and methods for treatment of mycoplasma and mycoplasma-like organism infections |
| EP1262185A1 (en) * | 2001-05-30 | 2002-12-04 | New Pharma Research Sweden AB | Synergistic antibiotic compositions |
| WO2003004098A1 (en) * | 2001-07-06 | 2003-01-16 | Sucampo Ag | Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent |
| UA79952C2 (en) * | 2001-12-10 | 2007-08-10 | Kabulesh Mafatlal Khamar | MYCOBACTERIUM w APPLICATIONS FOR CANCER TREATMENT |
| AUPS017702A0 (en) * | 2002-01-25 | 2002-02-14 | Atopic Pty Ltd | Methods and compositions for the treatment of asthma and related disorders |
| AUPS088702A0 (en) * | 2002-03-04 | 2002-03-28 | Borody, Thomas Julius | Electrolyte purgative |
| WO2003075852A2 (en) * | 2002-03-07 | 2003-09-18 | Advancis Pharmaceuticals Corporation | Antibiotic composition |
| US20040077533A1 (en) * | 2002-05-23 | 2004-04-22 | Sayada Chalom B. | Methods and compositions for treating bacterial infections and diseases associated therewith |
| AU2003265241A1 (en) * | 2002-05-23 | 2003-12-12 | Activbiotics, Inc. | Methods of treating bacterial infections and diseases associated therewith |
| US20090149453A1 (en) * | 2002-05-23 | 2009-06-11 | Activbiotics Pharma Llc | Methods and compositions for treating bacterial infections and diseases associated therewith |
| US6916627B2 (en) * | 2002-11-27 | 2005-07-12 | St. Jude Children's Research Hospital | ATM kinase compositions and methods |
| US7108992B2 (en) * | 2002-11-27 | 2006-09-19 | St. Jude Children's Research Hospital | ATM kinase compositions and methods |
| WO2004054548A1 (en) * | 2002-12-12 | 2004-07-01 | Activbiotics,Inc. | Method and reagents for treating or preventing atherosclerosis and diseases associated therewith |
| WO2004054513A2 (en) * | 2002-12-12 | 2004-07-01 | Activbiotics, Inc. | Methods and compositions for treating and preventing ear infections |
| US20050013835A1 (en) * | 2003-07-15 | 2005-01-20 | Pfizer Inc. | Stable non-dihydrate azithromycin oral suspensions |
| RU2254123C2 (ru) * | 2003-08-11 | 2005-06-20 | Государственное научное учреждение Институт экспериментальной ветеринарии Сибири и Дальнего Востока Сибирского отделения Россельхозакадемии (ГНУ ИЭВСиДВ СО РАСХН) | Препарат для лечения гемобартонеллеза кошек и способ его применения |
| WO2005027961A2 (en) * | 2003-09-23 | 2005-03-31 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Chlamydia pmpd autotransporter and its role as adhesin |
| NZ549661A (en) | 2004-02-06 | 2010-07-30 | Pharmatel R & D Pty Ltd As Tru | Use of aminosalicylates in diarrhoea-predominant irritable bowel syndrome |
| JP5009152B2 (ja) * | 2004-05-28 | 2012-08-22 | サリックス ファーマシューティカルズ， インコーポレイテッド | 放射線誘発性腸炎の予防、処置、および回復 |
| JP5047797B2 (ja) | 2004-09-30 | 2012-10-10 | コヴァロン・テクノロジーズ・インコーポレーテッド | 非接着性の弾性ゼラチンマトリックス |
| JPWO2006057429A1 (ja) * | 2004-11-24 | 2008-06-05 | ナノキャリア株式会社 | ブロックコポリマーのモーフォロジーの変化方法 |
| US7452872B2 (en) * | 2005-08-24 | 2008-11-18 | Salix Pharmaceuticals, Inc. | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
| CN101247812A (zh) * | 2005-08-24 | 2008-08-20 | 萨利克斯药品公司 | 巴柳氮制剂及其生产和应用 |
| US8921344B2 (en) * | 2006-11-03 | 2014-12-30 | Salix Pharmaceuticals, Inc. | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
| FR2891744B1 (fr) * | 2005-10-06 | 2009-10-09 | France Etat Armement | Application a la chimioprophylaxie du paludisme d'une association de chloroquine et de doxycycline |
| US8647673B2 (en) * | 2007-07-24 | 2014-02-11 | Wayne State University | Nanoparticles for imaging and treating chlamydial infection |
| ES2645692T3 (es) | 2008-11-11 | 2017-12-07 | The Board Of Regents,The University Of Texas System | Microcápsulas de rapamicina y su uso para el tratamiento del cáncer |
| GB2548296A (en) * | 2009-10-22 | 2017-09-13 | Borody Thomas J | Novel parasite therapy |
| US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
| US8497256B2 (en) | 2010-04-26 | 2013-07-30 | Salix Pharmaceuticals, Ltd | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males |
| NZ611868A (en) | 2010-12-13 | 2015-11-27 | Salix Pharmaceuticals Inc | Gastric and colonic formulations and methods for making and using them |
| CN103813977A (zh) * | 2011-08-16 | 2014-05-21 | 普拉克生化公司 | 可用于发酵液处理的通过用盐酸沉淀从羧酸镁盐中回收羧酸的方法 |
| EP2877163B1 (en) | 2012-07-27 | 2019-03-20 | Redhill Biopharma Ltd. | Formulations and methods of manufacturing formulations for use in colonic evacuation |
| WO2014160328A1 (en) | 2013-03-13 | 2014-10-02 | The Board Of Regents Of The University Of Texas System | Mtor inhibitors for prevention of intestinal polyp growth |
| AU2014373683B2 (en) | 2013-12-31 | 2020-05-07 | Rapamycin Holdings, Llc | Oral rapamycin nanoparticle preparations and use |
| US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
| MX382754B (es) * | 2015-10-06 | 2025-03-13 | Redhill Biopharma Ltd | Terapias combinadas para tratar el cancer. |
| US11197872B2 (en) | 2017-04-21 | 2021-12-14 | Lunella Biotech, Inc. | Vitamin C and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCs) |
| WO2018195446A1 (en) | 2017-04-21 | 2018-10-25 | Lisanti Michael P | Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy |
| EP3624840A4 (en) | 2017-05-19 | 2021-03-10 | Lunella Biotech, Inc. | ANTIMITOSCINE: TARGETED INHIBITORS OF MITOCHONDRIAL BIOGENESIS TO DESCRIBE CANCER STEM CELLS |
| US12006553B2 (en) | 2017-05-19 | 2024-06-11 | Lunella Biotech, Inc. | Companion diagnostics for mitochondrial inhibitors |
| EP3644988B1 (en) | 2017-06-26 | 2023-02-22 | Lunella Biotech, Inc. | Mitoketoscins: mitochondrial-based therapeutics targeting ketone metabolism in cancer cells |
| CN111757732A (zh) * | 2018-02-01 | 2020-10-09 | 消化系统疾病中心 | 用于治疗感染性动脉疾病和相关病状的组合物 |
| RU2684728C1 (ru) * | 2018-05-21 | 2019-04-12 | федеральное государственное бюджетное образовательное учреждение высшего образования "Ставропольский государственный аграрный университет" | Препарат на основе пчелиного маточного молочка для лечения мелких домашних животных при гемобартонеллезе |
| WO2021191456A1 (en) * | 2020-03-27 | 2021-09-30 | Vectura Limited | Compositions for the treatment of a respiratory condition |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US588550A (en) | 1897-08-24 | Alarm-clock | ||
| GB1463550A (en) | 1974-08-06 | 1977-02-02 | Bodrero G | Pharmaceutical composition |
| GB2189699A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
| FI883067A7 (fi) * | 1988-06-27 | 1989-12-28 | Labsystems Oy | Foerfarande foer behandling av koronarkaerlsjukdom. |
| US5914132A (en) | 1993-02-26 | 1999-06-22 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| GB9416600D0 (en) | 1994-08-17 | 1994-10-12 | Smithkline Beecham Plc | Pharmaceutical formulation |
| US5624704A (en) | 1995-04-24 | 1997-04-29 | Baylor College Of Medicine | Antimicrobial impregnated catheters and other medical implants and method for impregnating catheters and other medical implants with an antimicrobial agent |
| US6080757A (en) * | 1996-06-06 | 2000-06-27 | Pfizer Inc | Antibiotic quinolones and derivatives |
| US6838552B1 (en) * | 1997-08-14 | 2005-01-04 | Vanderbilt University | Diagnosis and management of infection caused by Chlamydia |
| US5811121A (en) | 1997-01-29 | 1998-09-22 | Eastman Chemical Company | PH-sensitive coatings based on cellulose acetoacetate |
| JP2002512622A (ja) * | 1997-05-06 | 2002-04-23 | バンダービルト ユニバーシティー | クラミジアにより引き起こされる感染の診断および管理のための抗クラミジア剤の組成物 |
-
1998
- 1998-06-30 AU AUPP4376A patent/AUPP437698A0/en not_active Abandoned
-
1999
- 1999-06-20 US US09/736,029 patent/US6475518B1/en not_active Expired - Lifetime
- 1999-06-30 AU AU45919/99A patent/AU757293B2/en not_active Expired
- 1999-06-30 EP EP99928901A patent/EP1093363B1/en not_active Expired - Lifetime
- 1999-06-30 ES ES99928901T patent/ES2278449T3/es not_active Expired - Lifetime
- 1999-06-30 JP JP2000557825A patent/JP4651816B2/ja not_active Expired - Lifetime
- 1999-06-30 NZ NZ509504A patent/NZ509504A/en not_active IP Right Cessation
- 1999-06-30 CA CA2684402A patent/CA2684402C/en not_active Expired - Lifetime
- 1999-06-30 CA CA2336593A patent/CA2336593C/en not_active Expired - Lifetime
- 1999-06-30 AT AT99928901T patent/ATE345115T1/de not_active IP Right Cessation
- 1999-06-30 DE DE69934010T patent/DE69934010T2/de not_active Expired - Lifetime
- 1999-06-30 ES ES06023648.6T patent/ES2514469T3/es not_active Expired - Lifetime
- 1999-06-30 EP EP06023648.6A patent/EP1754472B1/en not_active Expired - Lifetime
- 1999-06-30 WO PCT/AU1999/000528 patent/WO2000001378A1/en not_active Ceased
-
2010
- 2010-03-29 JP JP2010074109A patent/JP5335726B2/ja not_active Expired - Lifetime
-
2013
- 2013-04-02 JP JP2013076511A patent/JP2013147504A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010174030A5 (enExample) | ||
| IL211120A (en) | Compound, tetracycline converted at position 7c with fluorine, a pharmaceutical preparation containing it and its use in the preparation of drugs for the treatment of bacteria-caused infection | |
| BRPI0815577A2 (pt) | Peptídeo foxm1 e agente medicinal compreendendo o mesmo. | |
| JP2010285439A5 (enExample) | ||
| BRPI0821855A2 (pt) | Composto, agente farmacêutico, uso de um composto inibidor de dna girase bacteriana, agente antibacteriano, e, agente terapêutico para doença infecciosa | |
| IL213528A (en) | Use of digestive enzymes in the preparation of a drug for the treatment of golden staphylococcal infections | |
| BRPI0806531A2 (pt) | Composto, composição farmacêutica, agente terapêutico, e, uso do composto. | |
| BR112012004967A2 (pt) | forma de dosagem oral, compreendendo pelo menos um agente biologicamente ativo, substâncias auxiliares da formulação e partículas magnetizáveis | |
| WO2008116813A3 (en) | Combination medicaments for treating bacterial infections | |
| JP2016507532A5 (enExample) | ||
| IL218277B (en) | Tetracycline compounds, pharmaceutical preparations containing them and their use for the preparation of medicines for the treatment and prevention of infection | |
| WO2008020227A3 (en) | Antibacterial pyrrolecarboxamides | |
| IL187904A (en) | Use of quinoline derivatives for the preparation of bacterial preparations for the treatment of bacteria caused by bacteria | |
| JP2007510757A5 (enExample) | ||
| BRPI0816236A2 (pt) | Peptídeo cdh3 e agente medicinal contendo o mesmo | |
| JP2015532923A5 (enExample) | ||
| JP2009539970A5 (enExample) | ||
| JP2018500387A5 (enExample) | ||
| IN2014CN02908A (enExample) | ||
| NZ611026A (en) | Pharmaceutical composition comprising citrate and bicarbonate salts, and use thereof for treating cystinuria | |
| WO2007116102A3 (en) | Therapeutic composition and use | |
| IL197783A (en) | Polycyclic compounds, preparations containing them and polycyclic compounds for use in the treatment of synthetic respiratory virus infections | |
| WO2008097364A3 (en) | Use of oritavancin for prevention and treatment of anthrax | |
| IL210975A (en) | Annapomapungin History, Pharmaceuticals Containing Them and Their Use in Preparing Medicines to Treat Fungal Infections | |
| JP2010525044A5 (enExample) |